Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 3/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30001711 | 1.00 | KMT2A (0.53) | KMT2AEPHX2CASP3OPRD1CXCR2 | |
| SCHEMBL27333025 | 0.99 | KMT2A (0.52) | KMT2AEPHX2CASP3OPRD1CXCR2 | |
| SCHEMBL30877996 | 0.99 | KMT2A (0.52) | KMT2AEPHX2CASP3OPRD1CXCR2 | |
| SCHEMBL21522985 | 0.91 | KMT2A (0.57) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL20628606 | 0.90 | KMT2A (0.51) | KMT2AEPHX2CASP3OPRD1CXCR2 | |
| SCHEMBL20603546 | 0.89 | KMT2A (0.50) | KMT2AEPHX2CASP3OPRD1CXCR2 | |
| SCHEMBL21689327 | 0.87 | KMT2A (0.55) | KMT2AEPHX2CASP3OPRD1CXCR2 | |
| SCHEMBL29776526 | 0.86 | KMT2A (0.52) | KMT2AEPHX2CASP3OPRD1CXCR2 | |
| SCHEMBL16485219 | 0.86 | KMT2A (0.52) | KMT2AEPHX2CASP3OPRD1CXCR2 | |
| SCHEMBL29061468 | 0.86 | KMT2A (0.47) | KMT2AEPHX2CASP3OPRD1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714956-A2 | IMPROVED METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2026-03-25 | — | — | EP | disclosed |
| US-12503489-B2 | Method for producing antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-12-23 | — | — | US | disclosed |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-3677589-B1 | IMPROVED METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2025-11-26 | — | — | EP | disclosed |
| US-20250257146-A1 | ANTI-TROP2 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-08-14 | — | — | US | disclosed |
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4538372-A2 | ANTI-TROP2 ANTIBODY | Daiichi Sankyo Company, Limited (JP) | 2025-04-16 | — | — | EP | disclosed |
| EP-3424955-B1 | METHOD FOR PRODUCING AN ANTI-TROP2 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2025-04-09 | — | — | EP | disclosed |
| EP-4524154-A2 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2025-03-19 | — | — | EP | disclosed |
| US-20250064954-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2025-02-27 | — | — | US | disclosed |
| EP-3088419-A1 | ANTI-TROP2 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-11-02 | — | — | EP | disclosed |
| US-20160297890-A1 | ANTI-TROP2 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-10-13 | — | — | US | disclosed |
| US-20160297890-A1 | ANTI-TROP2 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-10-13 | — | — | US | disclosed |
| US-20160279259-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-29 | — | — | US | disclosed |
| US-20160279259-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-29 | — | — | US | disclosed |
| US-20150297748-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150297748-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| WO-2015155998-A1 | ANTI-HER3 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015155998-A1 | ANTI-HER3 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-15 | — | — | WO | disclosed |
| EP-2907824-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | STING1, CGAS, CDA | KMT2A 2775/4885EPHX2 1647/4885CASP3 2484/4885 |
| US-20250257146-A1 | ANTI-TROP2 ANTIBODY-DRUG CONJUGATE | TAGLN2, TNNT2, TPM4 | KMT2A 1096/4885EPHX2 2212/4885CASP3 3103/4885 |
| US-20250064954-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | KMT2A 4385/4885EPHX2 2214/4885CASP3 4527/4885 |
| US-12503489-B2 | Method for producing antibody-drug conjugate | UGT1A9, ALB, MRPL21 | KMT2A 2459/4885EPHX2 968/4885CASP3 2801/4885 |
| US-20160279259-A1 | ANTIBODY-DRUG CONJUGATE | LANCL2, LANCL1, LCLAT1 | KMT2A 588/4885EPHX2 2444/4885CASP3 2168/4885 |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | KMT2A 710/4885EPHX2 4662/4885CASP3 3644/4885 |
| US-20150297748-A1 | ANTIBODY-DRUG CONJUGATE | LANCL2, LANCL1, LCLAT1 | KMT2A 588/4885EPHX2 2444/4885CASP3 2168/4885 |
| US-20160297890-A1 | ANTI-TROP2 ANTIBODY-DRUG CONJUGATE | TAGLN2, TNNT2, TPM4 | KMT2A 1096/4885EPHX2 2212/4885CASP3 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.